Method for minimizing the uterotrophic effect of tamoxifen and tamoxifen analogs

Abstract

The present invention provides a method of minimizing the uterotrophic effect of non-steroidal antiestrogen compounds of formula II ##STR1## wherein either R.sup.4 is H or a lower alkyl radical and R.sup.5 is a lower alkyl radical, or R.sup.4 and R.sup.5 are joined together with the adjacent nitrogen atom to form a heterocyclic radical; R.sup.6 is H or a lower alkyl radical; R.sup.7 is H, halo, OH, a lower alkyl radical, or is a buta-1,3-dienyl radical which together with the adjacent benzene ring forms a naphthyl radical; R.sup.8 is H or OH; and n is 2; or a pharmaceutically acceptable salt thereof, wherein said formula II compound is administered to a woman for the treatment or prevention of breast carcinoma, comprising concurrently or sequentially administering to said woman a compound of formula I ##STR2## wherein R.sup.1 and R.sup.3 are independently hydrogen, --CH.sub.3, --CO--(C.sub.1 -C.sub.6 alkyl), or --CO--Ar, in which Ar is optionally substituted phenyl; and R.sup.2 is selected from the group consisting of pyrrolidino, hexamethyleneimino, and piperidino; or pharmaceutically acceptable salt or solvate thereof. The present invention further provides pharmaceutical compositions comprising a compound of formula I and a compound of formula II together with a pharmaceutically acceptable carrier, excipient, or diluent.

Dependencies are inferred from the claim text.